Metabolomics: A revolution for novel cancer marker identification

Combinatorial Chemistry and High Throughput Screening

Volumn 15, Issue 3, 2012, Pages 266-275

  Bu, Qian ^a   Huang, Yina ^a   Yan, Guangyan ^a   Cen, Xiaobo ^a   Zhao, Ying Lan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Biomarker identification; Cancer; Metabolomics

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLUTATHIONE; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; TUMOR MARKER;

BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TECHNOLOGY;

ANIMALS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863262945     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/138620712799218563     Document Type: Review

References (79)

1. Nicholson, J.; Lindon, J.; Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 1999, 29 (11), 1181-1189.
2. Van, Q.; Veenstra T. How close is the bench to the bedside? Metabolic profiling in cancer research. Genome Med., 2009, 1 (1), 5.
3. Nieto, J.; Grossbard, M.; Kozuch, P. Metastatic pancreatic cancer 2008: is the glass less empty? The Oncologist, 2008, 13 (5), 562-576. (Pubitemid 351872873)
4. Jain, K. Cancer biomarkers: current issues and future directions. Curr. Opin. Mol. Ther., 2007, 9 (6), 563-571. (Pubitemid 350179096)
5. Quinones, M.; Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis., 2009, 35 (2), 165-176.
6. Fan, T.; Lane A.; Higashi R. The promise of metabolomics in cancer molecular therapeutics. Curr. Opin. Mol. Ther., 2004, 6 (6), 584-592. (Pubitemid 40074978)
7. Griffin, J.; Shockcor, J. Metabolic profiles of cancer cells. Nat. Rev. Cancer, 2004, 4 (7), 551-561. (Pubitemid 38868624)
8. Clayton, T.; Lindon, J.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J.; Le Net, J.; Baker, D.; Walley, R. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature, 2006, 440 (7087), 1073-1077.
9. Beckonert, O.; Keun, H.; Ebbels, T.; Bundy, J.; Holmes, E.; Lindon, J.; Nicholson, J. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc., 2007, 2 (11), 2692-2703.
10. Spratlin, J.; Serkova, N.; Eckhardt S. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res., 2009, 15 (2), 431.
11. Holmes, P.; Bohrer, M.; Kohn, J. Exploration of polymethacrylate structure-property correlations: Advances towards combinatorial and high-throughput methods for biomaterials discovery. Prog. Polym. Sci., 2008, 33 (8), 787-796.
12. Skordi, E.; Wilson, I.; Lindon, J.; Nicholson, J. Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1 H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism. Xenobiotica, 2004, 34 (11), 1075-1089. (Pubitemid 40070107)
13. Kaddurah-Daouk, R.; Kristal, B.; Weinshilboum, R. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol., 2008, 48, 653-683. (Pubitemid 351738167)
14. Kristal, B.; Shurubor, Y.; Kaddurah-Daouk, R., Matson, W. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol. Biol., 2007, 358, 159-174.
15. Schmidt, C. Metabolomics takes its place as latest up-and-coming "omic" science. J. Natl. Cancer Inst., 2004, 96 (10), 732-734. (Pubitemid 38771813)
16. Wishart, D.S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A.C.; Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.; Coutouly, M.A.; Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard, P.; Amegbey, G.; Block, D.; Hau, D.D.; Wagner, J.; Miniaci, J.; Clements, M.; Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan, G.E.; Macinnis, G.D.; Weljie, A.M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner, R.; Li, L.; Marrie, T.; Sykes, B.D.; Vogel, H.J.; Querengesser, L. HMDB: the human metabolome database. Nucleic Acids Res., 2007, 35, D521-527.
17. Wishart, D.S.; Knox, C.; Guo, A.C.; Eisner, R.; Young, N.; Gautam, B.; Hau, D.D.; Psychogios, N.; Dong, E.; Bouatra, S.; Mandal, R.; Sinelnikov, I.; Xia, J.; Jia, L.; Cruz, J.A.; Lim, E.; Sobsey, C.A.; Shrivastava, S.; Huang, P.; Liu, P.; Fang, L.; Peng, J.; Fradette, R.; Cheng, D.; Tzur, D.; Clements, M.; Lewis, A.; De Souza, A.; Zuniga, A.; Dawe, M.; Xiong, Y.; Clive, D.; Greiner, R.; Nazyrova, A.; Shaykhutdinov, R.; Li, L.; Vogel, H.J.; Forsythe, I. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res., 2009, 37, D603-610.
18. 1H-NMR-based metabolomics. Expert Rev. Mol. Diagn., 2006, 6 (5), 717-731.
19. Wikoff, W.; Pendyala, G.; Siuzdak, G.; Fox, H. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J. Clin. Invest., 2008, 118 (7), 2661-2669. (Pubitemid 351949793)
20. German, J.; Hammock, B.; Watkins, S. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics, 2005, 1 (1), 3-9.
21. Whitehead, T.; Kieber-Emmons, T. Applying in vitro NMR spectroscopy and H-1 NMR metabonomics to breast cancer characterization and detection. Prog. Nucl. Magn. Reson. Spectrosc., 2005, 47, 165-174. (Pubitemid 41677699)
22. Morvan, D.; Demidem, A.; Papon, J.; De Latour, M.; Madelmont, J. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Cancer Res., 2002, 62 (6), 1890-1897. (Pubitemid 34408518)
23. Sitter, B.; Sonnewald, U.; Spraul, M.; Fjsne, H.; Gribbestad, I. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed., 2002, 15 (5), 327-337. (Pubitemid 34960100)
24. Sitter, B.; Bathen, T.; Singstad, T.; Fjosne, H.; Lundgren, S.; Halgunset, J.; Gribbestad, I. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR in Biomed., 2010, 23 (4), 424-431.
25. Giskeødegård, G.F.; Grinde, M.T.; Sitter, B.; Axelson, D.E.; Lundgren, S.; Fjøsne, H.E.; Dahl, S.; Gribbestad, I.S.; Bathen, T.F. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J. Proteome Res., 2010, 9 (2), 972-979.
26. 1H-NMRS-based metabolomics study. Cancer Res., 2009, 69 (9), 3731-3735.
27. Sreekumar, A.; Poisson, L.; Rajendiran, T.; Khan, A.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R.; Li, Y. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457 (7231), 910-914.
28. 1H HR-MAS spectroscopy. Magn. Reson. Med., 2006, 55 (6), 1257-1264.
29. Monleon, D.; Morales, J.M.; Gonzalez-Darder, J.; Talamantes, F.; Cortes, O.; Gil-Benso, R.; Lopez-Gines, C.; Cerda-Nicolas, M.; Celda, B. Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J. Proteome Res., 2008, 7 (7), 2882-2888.
30. Zhang, X.; Wei, D.; Yap, Y.; Li, L.; Guo, S.; Chen, F. Mass spectrometry-based "omics" technologies in cancer diagnostics. Mass Spectrom. Rev., 2007, 26 (3), 403-431. (Pubitemid 46750377)
31. Clarke, C.; Haselden, J. Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol., 2008, 36 (1), 140-147.
32. Nicholson, J.; Lindon, J. Systems biology: metabonomics. Nature, 2008, 455 (7216), 1054-1056.
33. Sajda, P. Machine learning for detection and diagnosis of disease. Annu. Rev. Biomed. Eng., 2006, 8, 573-565.
34. Kell, D.; Brown, M.; Davey, H.; Dunn, W.; Spasic, I.; Oliver, S. Metabolic footprinting and systems biology: the medium is the message. Nat. Rev. Microbiol., 2005, 3 (7), 557-565. (Pubitemid 40908875)
35. Shockcor, J.; Holmes, E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top Med. Chem., 2002, 2 (1), 35-51.
36. Fuchs, J.; Podda, M. Encyclopedia of medical genomics and proteomics vol 2004: Informa Healthcare)
37. Lindon, J.; Holmes, E.; Bollard, M.; Stanley, E.; Nicholson, J. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Int. J. Food Sci.Nutr., 2004, 9 (1), 1-31. (Pubitemid 38660013)
38. Lindon, J.; Nicholson, J. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. TrAC Trend Anal. Chem., 2008, 27 (3), 194-204. (Pubitemid 351436617)
39. Di Leo, A.; Claudino, W.; Colangiuli, D.; Bessi, S.; Pestrin, M.; Biganzoli, L. New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann. Oncol., 2007, 18 (suppl 12), xii8-xii14.
40. Parkin, D.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108. (Pubitemid 40372904)
41. Morvan, D.; Demidem, A. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res., 2007, 67 (5), 2150.
42. 1H NMR-based metabolomics. Neoplasia, 2009, 11 (3), 269-276.
43. Sugimoto, M.; Wong, D.; Hirayama, A.; Soga, T.; Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics, 2010, 6 (1), 78-95.
44. 1H nuclear magnetic resonance spectroscopy of freeze-tolerant and freeze-intolerant earthworms exposed to frost. Cryoletters, 2003, 24 (6), 347-358.
45. Plumb, R.; Granger, J.; Stumpf, C.; Wilson, I.; Evans, J.; Lenz, E. Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences. The Analyst, 2003, 128 (7), 819-823. (Pubitemid 36897868)
46. Williams, R.; Eyton-Jones, H.; Farnworth, M.; Gallagher, R.; Provan, W. Effect of intestinal microflora on the urinary metabolic profile of rats: a 1 H-nuclear magnetic resonance spectroscopy study. Xenobiotica, 2002, 32 (9), 783-794.
47. Robosky, L.; Robertson, D.; David, B.; Rane, S.; Reily, M. In vivo toxicity screening programs using metabonomics. Comb.Chem. High Throughput Screen., 2002, 5 (8), 651-662. (Pubitemid 35387862)
48. Gavaghan, C.; Wilson, I.; Nicholson, J. Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS-DA. FEBS letters, 2002, 530 (1- 3), 191-196.
49. Bollard, M.; Keun, H.; Beckonert, O.; Ebbels, T.; Antti, H.; Nicholls, A.; Shockcor, J.; Cantor, G.; Stevens, G.; Lindon, J. Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol. Appl. Pharmacol., 2005, 204 (2), 135-151. (Pubitemid 40432371)
50. Griffin, J.; Walker, L.; Garrod, S.; Holmes, E.; Shore, R.; Nicholson, J. NMR spectroscopy based metabonomic studies on the comparative biochemistry of the kidney and urine of the bank vole (Clethrionomys glareolus), wood mouse (Apodemus sylvaticus), white toothed shrew (Crocidura suaveolens) and the laboratory rat. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 2000, 127 (3), 357-367.
51. Kim, Y.; Maruvada, P.; Milner, J. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol., 2008, 4 (1), 93-102. (Pubitemid 351372610)
52. Serkova, N.; Zhang, Y.; Coatney, J.; Hunter, L.; Wachs, M.; Niemann, C.; Mandell, M. Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation, 2007, 83 (4), 517-521. (Pubitemid 46667858)
53. Zhao, Y,;Lee W,;Xiao G. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev. Proteomics, 2009, 6 (2), 115- 118.
54. Erb, G.; Elbayed, K.; Piotto, M.; Raya, J.; Neuville, A.; Mohr, M.; Maitrot, D.; Kehrli, P.; Namer, I. Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn. Reson. Med., 2008, 59 (5), 959-965. (Pubitemid 351590507)
55. Nelson, S.; Cha, S. Imaging glioblastoma multiforme. The Cancer Journal, 2003, 9 (2), 134.
56. Parkin, D.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics 2005. CA Cancer J. Clin., 2005, 55, 74-108.
57. Llovet, J.M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. The Lancet, 2003, 362 (9399), 1907-1917. (Pubitemid 37518510)
58. Thorgeirsson, S.S.; Grisham, J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 2002, 31 (4), 339-346. (Pubitemid 35154440)
59. Davila, J.; Morgan, R.; Shaib, Y.; McGlynn, K.; El-Serag, H. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut, 2005, 54 (4), 533-539. (Pubitemid 40403031)
60. Gupta, S.; Bent, S,; Kohlwes, J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med., 2003, 139 (1), 46-50. (Pubitemid 38124619)
61. Xue, R.;Lin, Z.; Deng, C.; Dong, L.; Liu, T.; Wang, J.; Shen, X. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun.Mass Spec., 2008, 22 (19), 3061-3068.
62. 1H NMR©\based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci., 2009, 100 (4), 782-785.
63. Gorre, M.; Ellwood-Yen, K.; Chiosis, G.; Rosen, N.; Sawyers, C. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 2002, 100 (8), 3041-3044.
64. Gottschalk, S.; Anderson, N.; Hainz, C.; Eckhardt, S.; Serkova, N. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin.Cancer Res., 2004, 10 (19), 6661.
65. Nordström, A.; Lewensohn, R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol., 2010, 5 (1), 4-17.
66. 1H NMR studies of RD human cell infection with echovirus 11. NMR in Biomed., 2007, 20 (4), 422-428.
67. Janakiraman, M.; Vakiani, E.; Zeng, Z.; Pratilas, C.A.; Taylor, B.S.; Chitale, D.; Halilovic, E.; Wilson, M.; Huberman, K.; Ricarte Filho, J.C.; Persaud, Y.; Levine, D.A.; Fagin, J.A.; Jhanwar, S.C.; Mariadason, J.M.; Lash, A.; Ladanyi, M.; Saltz, L.B.; Heguy, A.; Paty, P.B.; Solit, D.B. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res., 2010, 70(14), 5901-5911.
68. Tsunematsu, T.; Kudo, Y.; Iizuka, S.; Ogawa, I.; Fujita, T.; Kurihara, H.; Abiko, Y.; Takata, T. RUNX3 has an oncogenic role in head and neck cancer. PLoS One, 2009, 4 (6), e5892.
69. Siyi, H.; Nathalie, D.; Zhenzhen, L.; Tao, L.; Cruz, V; Jone, G.; Ashok, P.; Shahriar, K. Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Molecular Cancer, 2010, 9, 30.
70. Murgia, C.; Pritchard, J.; Kim, S.; Fassati, A.; Weiss, R. Clonal origin and evolution of a transmissible cancer. Cell, 2006, 126 (3), 477-487. (Pubitemid 44163607)
71. Mithani, S.; Taube, J.; Zhou, S.; Smith, I.; Koch, W.; Westra, W.; Califano, J. Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. Clin. Cancer Res., 2007, 13 (15), 4331-4335. (Pubitemid 47219696)
72. Catto, J.;;Miah, S.; Owen, H.; Bryant, H.; Myers, K.; Dudziec, E.; Larre, S.; Milo. M.; Rehman, I.; Rosario, D. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res., 2009, 69 (21), 8472.
73. Yeoh, L.; Loh, C.; Gooi, B.; Singh, M.; Gam, L. Hydrophobic protein in colorectal cancer in relation to tumor stages and grades. World J. Gastroenterol., 2010, 16 (22), 2754-2763.
74. Ogino, S.; Cantor, M.; Kawasaki, T.; Brahmandam, M.; Kirkner, G.; Weisenberger, D.; Campan, M.; Laird, P.; Loda, M.; Fuchs, C. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Br. Med. J., 2006, 55 (7), 1000-1006. (Pubitemid 43962613)
75. Moreno, A.; Lopez, L.; Fabra, A.; Arus, C. 1H MRS markers of tumour growth in intrasplenic tumours and liver metastasis induced by injection of HT-29 cells in nude mice spleen. NMR in Biomed., 1998, 11 (3), 93- 106.
76. 1H NMR spectroscopy in conjunction with multivariate data analysis. J. Proteome Res., 2007, 6 (7), 2605- 2614.
77. 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia, 2010, 24 (4), 788-797.
78. Chen, J.; Wang, W.; Lv, S.; Yin, P.; Zhao, X.; Lu, X.; Zhang, F.; Xu, G. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Analytica Ahimica Acta, 2009, 650 (1), 3-9.
79. Kroemer, G.; Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13 (6), 472-482. (Pubitemid 351766797)